T cell therapy: feasibility in myeloma
About this module
Dr Rakesh Popat discusses the role of T cells in immunosurveillance and cancer and describes the potential benefits of different types of T cell therapy in myeloma.
Dr Popat is a Clinical Fellow supported by the National Institute for Health Research, University College London Hospitals Biomedical Research Centre.
CPD hours: 1
References
Gertz M (2015) When to recommend allogenenic transplant in multiple myeloma. Leuk Lymphoma 56: 2512-2517.
San Miguel J et al. (2015) Engineering anti-myeloma responses using affinity-enhanced TCR-engineered T cells. Cancer Cell 28: 281-283.
Lendval N et al. (2015) Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. Bone Marrow Transplant. 50: 770-780.
Rapoport A et al. (2015) NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific anti-tumor effects in myeloma. Nat. Med. 21: 914-921.
Rotolo A et al (2016) The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma. Br J Haematol. 173: 350-364.
Take the CPD Quiz
Sorry. You must be logged in to view this form.